New 2-Drug HIV Regimen Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Study Shows Patients Commonly Misdiagnosed with Multiple Sclerosis
Approximately 1 in 5 patients in a study were misdiagnosed with multiple sclerosis before being referred to treatment centers.
4. FDA Approves New Osteoporosis Therapy for Postmenopausal Women
Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.
3. Revcovi: A New Treatment Option for ADA-SCID
Adenosine deaminase is an ultra-rare and inherited disorder that is detrimental to the immune system and causes severe combined immune deficiency.
2. Senate Hearing Addresses Role of Pharmacy Benefit Managers in Drug Pricing
On Tuesday, a US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients.
1.FDA OKs 2-Drug HIV Treatment for Antiretroviral Therapy-Naïve Patients
With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
